[go: up one dir, main page]

MXPA02009984A - Metodo y composicion para el tratamiento del cancer mediante la administracion de agentes quimioterapeuticos que inducen la apoptosis. - Google Patents

Metodo y composicion para el tratamiento del cancer mediante la administracion de agentes quimioterapeuticos que inducen la apoptosis.

Info

Publication number
MXPA02009984A
MXPA02009984A MXPA02009984A MXPA02009984A MXPA02009984A MX PA02009984 A MXPA02009984 A MX PA02009984A MX PA02009984 A MXPA02009984 A MX PA02009984A MX PA02009984 A MXPA02009984 A MX PA02009984A MX PA02009984 A MXPA02009984 A MX PA02009984A
Authority
MX
Mexico
Prior art keywords
chemotherapeutic
tumor
composition
administration
treating cancer
Prior art date
Application number
MXPA02009984A
Other languages
English (en)
Inventor
Flashner-Barak Moshe
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MXPA02009984A publication Critical patent/MXPA02009984A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Las limitaciones de la tecnologia actual de los reservorios de quimioterapia pueden deberse a la retencion del quimioterapeutico solamente en la periferia del tumor o en la zona de inyeccion a causa de la pobre penetracion y distribucion del quimioterapeutico como resultado de la elevada presion del fluido intersticial del neoplasma. Un efecto anti-tumoral mas potente puede lograrse dirigiendo el quimioterapeutico directamente al tumor, es decir, intratumoralmente, antes que por infusion sistematica. Se especula que la entrada de las microesferas al tumor solido puede incrementarse aun mas si la inyeccion inicial de droga administrada para inducir la apoptosis consiste en una forma mas soluble de Taxol, es decir, paclitaxel/HSA, un complejo de Taxol y albumina, aumentando asi la apoptosis a lo largo de otros gradientes de presion. Ahora reportamos la aplicacion de un quimioterapeutico anti-cancerigeno, tal como paclitaxel, usando una composicion para la administracion local, a un paciente que tiene un tumor, de un quimioterapeutico anti-tumoral, tal como un reservorio quimiotrapeutico. La presente invencion comprende una pluralidad de microesferas que incorporan el quimioterapeutico anti-tumoral; y, una solucion de suspension que rodea las microesferas. Se saca ventaja de las proteinas de plasma, tal como HSA, para que actuen como un reservorio de liberacion lenta del quimioterapeutico anti-cancerigeno, tal como paclitaxel. La presente invencion proporciona una composicion para administrar un quimioterapeutico anti-tumoral como un reservorio quimioterapeutico a un paciente que presenta un tumor, la composicion comprende: una pluralidad de esferas que incorporan el quimioterapeutico anti-tumoral; y, una solucion de suspension que rodea las microesferas. La realizacion preferida consiste en una pluralidad de microesferas elaboradas a partir de una matriz polimerica biodegradable. Alternativamene, los reservorios pueden consistir en una pluralidad de microesferas elaboradas a partir de polimeros que no son biodegradables. La presente invencion proporciona ademas un metodo para la administracion de un quimioterapeutico anti-tumoral a un paciente que presenta un tumor, que comprende los pasos de aplicar el quimioterapeutico anti-tumoral como un reservorio quimioterapeutico para el tumor; y, liberar el quimioterapeutico anti-tumoral del reservorio quimioterapeutico a un espacio intersticial del tumor en una cantidad terapeuticamente efectiva, donde el reservorio quimioterapeutico incluye una pluralidad de microesferas que incorporan el quimioterapeutico anti-tumoral y una solucion de suspension que rodea las microesferas.
MXPA02009984A 2000-04-10 2001-04-10 Metodo y composicion para el tratamiento del cancer mediante la administracion de agentes quimioterapeuticos que inducen la apoptosis. MXPA02009984A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19592000P 2000-04-10 2000-04-10
PCT/US2001/011688 WO2001076567A1 (en) 2000-04-10 2001-04-10 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents

Publications (1)

Publication Number Publication Date
MXPA02009984A true MXPA02009984A (es) 2004-09-10

Family

ID=22723363

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02009984A MXPA02009984A (es) 2000-04-10 2001-04-10 Metodo y composicion para el tratamiento del cancer mediante la administracion de agentes quimioterapeuticos que inducen la apoptosis.

Country Status (19)

Country Link
US (1) US20020041888A1 (es)
EP (1) EP1274404A1 (es)
JP (1) JP2004507451A (es)
KR (1) KR20030008368A (es)
CN (1) CN1438882A (es)
AU (1) AU2001253334A1 (es)
BR (1) BR0110150A (es)
CA (1) CA2406484A1 (es)
CZ (1) CZ20023333A3 (es)
EA (1) EA200201068A1 (es)
HU (1) HUP0302296A2 (es)
IL (1) IL152180A0 (es)
MX (1) MXPA02009984A (es)
NO (1) NO20024867L (es)
PL (1) PL366035A1 (es)
SK (1) SK14452002A3 (es)
WO (1) WO2001076567A1 (es)
YU (1) YU77002A (es)
ZA (1) ZA200208167B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
KR20050026699A (ko) * 2002-04-26 2005-03-15 테바 파마슈티컬 인더스트리즈 리미티드 종양내 전달을 위한 마이크로입자 약학 조성물
CN1319525C (zh) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 紫杉醇-海藻酸钠微球血管栓塞剂及其制备
US8940311B2 (en) * 2004-10-21 2015-01-27 Tae-Hong Lim In situ controlled release drug delivery system
KR101976003B1 (ko) 2005-02-18 2019-05-09 아브락시스 바이오사이언스, 엘엘씨 치료제의 조합 및 투여 방식, 및 조합 요법
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US9233094B2 (en) 2005-05-04 2016-01-12 Medigene Ag Method of administering a cationic liposomal preparation
AU2007228984B2 (en) 2006-03-22 2012-05-03 Syncore Biotechnology Co., Ltd Treatment of triple receptor negative breast cancer
CA3087813A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of treating cancer
KR20190109593A (ko) 2010-03-29 2019-09-25 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
MY162903A (en) 2010-06-04 2017-07-31 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
WO2012094620A2 (en) * 2011-01-09 2012-07-12 Anp Technologies, Inc. Hydrophobic molecule-induced branched polymer aggregates and their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4345588A (en) * 1979-04-23 1982-08-24 Northwestern University Method of delivering a therapeutic agent to a target capillary bed
US4492720A (en) * 1983-11-15 1985-01-08 Benjamin Mosier Method of preparing microspheres for intravascular delivery
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins

Also Published As

Publication number Publication date
AU2001253334A1 (en) 2001-10-23
HUP0302296A2 (hu) 2003-10-28
WO2001076567A1 (en) 2001-10-18
NO20024867D0 (no) 2002-10-09
CZ20023333A3 (cs) 2003-06-18
ZA200208167B (en) 2004-02-10
NO20024867L (no) 2002-12-06
CN1438882A (zh) 2003-08-27
EP1274404A1 (en) 2003-01-15
CA2406484A1 (en) 2001-10-18
PL366035A1 (en) 2005-01-24
US20020041888A1 (en) 2002-04-11
EA200201068A1 (ru) 2003-12-25
JP2004507451A (ja) 2004-03-11
IL152180A0 (en) 2003-05-29
YU77002A (sh) 2005-09-19
KR20030008368A (ko) 2003-01-25
BR0110150A (pt) 2004-04-27
SK14452002A3 (sk) 2003-07-01

Similar Documents

Publication Publication Date Title
MX2007003795A (es) Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades.
MXPA02009984A (es) Metodo y composicion para el tratamiento del cancer mediante la administracion de agentes quimioterapeuticos que inducen la apoptosis.
SG166775A1 (en) Combinations and modes of administration of therapeutic agents and combination therapy
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
WO2000049937A3 (en) Trpm-2 antisense therapy
MXPA05012155A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
IL244727A0 (en) Methods and preparations using immunomodulatory compounds for the treatment and management of cancer and other diseases
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
YU13603A (sh) Postupci tretiranja poremećaja povenzanih sa bcl-2 primenom bcl-2 antisens oligomera
IL153014A0 (en) Barbituric acid analogs as therapeutic agents
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
WO2001039762A3 (en) Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system
PL365285A1 (en) Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
MXPA02004676A (es) Un metodo para quimioprevencion de cancer de prostata.
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
MXPA02002681A (es) Uso de metabolitos de acido alfa-linolenico para el tratamiento o prevencion del cancer.
MXPA05003551A (es) Composiciones y metodos para el tratamiento de prostata y otros canceres.
IL151628A0 (en) Combination therapies with vascular damaging activity
WO2006043083A8 (en) Liposomes enclosing a radionuclide and a cytotoxic agent for combination therapy
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
EP1545479A4 (en) EZETIMIB COMPOSITIONS AND METHOD FOR THE TREATMENT OF CHOLESTERIN-ASSOCIATED GOOD AND EVIL TUMORS
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.